BACKGROUND: The EORTC-STBSG coordinated two large trials of adjuvant chemotherapy(CT) in localized high grade soft @entity242 (STS). Both studies failed to demonstrate any benefit on @entity3012 . The aim of the analysis of these two trials was to identify subgroups of @entity1 who may benefit from adjuvant CT. @entity1 AND METHODS: Individual @entity1 data from two EORTC trials comparing @entity632 -based CT to observation only in completely resected STS (large resection, R0/marginal resection, R1) were pooled. Prognostic factors were assessed by univariate and multivariate analysis. @entity1 outcomes were subsequently compared between the two groups of @entity1 according to each analysed factor. RESULTS: A total of 819 @entity1 had been enrolled with a median follow-up of 8.2 years. @entity5 size, high histological grade and R1 resection emerged as independent adverse prognostic factors for @entity4434 and @entity3012 . Adjuvant CT is an independent favourable prognostic factor for @entity4434 but not for @entity3012 . A significant interaction between benefit of adjuvant CT and age, gender and R1 resection was observed for @entity4434 and @entity3012 . Males and @entity1 >40years had a significantly better @entity4434 in the treatment arms, while adjuvant CT was associated with a marginally worse @entity3012 in females and @entity1 <40years. @entity1 with R1 resection had a significantly better @entity4434 and @entity3012 favouring adjuvant CT arms. CONCLUSION: Adjuvant CT is not associated with a better overall survival in young @entity1 or in any pathology subgroup. Poor quality of initial surgery is the most important prognostic and predictive factor for utility of adjuvant CT in STS. Based on these data, we conclude that adjuvant CT for STS remains an investigational procedure and is not a routine standard of care.

XXXX -based adjuvant chemotherapy in soft @entity242 : pooled analysis of two STBSG-EORTC phase III clinical trials.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient', 'PATIENTS', 'Patient'] @entity632 :: ('MESH:D004317', 'Chemical') :: ['doxorubicin'] @entity242 :: ('MESH:D012509', 'Disease') :: ['tissue sarcoma'] @entity3012 :: ('MESH:C567932', 'Disease') :: ['OS'] @entity5 :: ('MESH:D009369', 'Disease') :: ['Tumor'] @entity4434 :: ('MESH:D005198', 'Disease') :: ['RFS']
@entity632 :: (MESH:D004317,Chemical) :: ['Doxorubicin']
